PSA screening leads to overdiagnosis, study saysBMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7355.61/a (Published 13 July 2002) Cite this as: BMJ 2002;325:61
- Deborah Josefson
Routine screening for prostate cancer using the prostate specific antigen (PSA) test, is responsible for the observed increased epidemiological incidence of the disease, says a new report (Journal of the National Cancer Institute 2002;94:981-90).
Moreover, PSA screening causes overdiagnosis rates of the disease in about 29% of white men and 44% of black men, so many of those whose cancers were diagnosed through PSA screening would likely have died of something other than prostate cancer.
As prostate cancer treatment itself causes …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial